Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Novartis_Pharmaceuticals_Corporation
|
| gptkbp:activities |
P I3 K inhibitor
|
| gptkbp:approves |
gptkb:2019
gptkb:FDA |
| gptkbp:can_be_used_with |
gptkb:letrozole
|
| gptkbp:clinical_trial |
gptkb:SOLAR-1
Phase III |
| gptkbp:contraindication |
severe hepatic impairment
hypersensitivity to alpelisib |
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:duration |
until disease progression
|
| gptkbp:events |
monitor blood glucose levels
monitor for diarrhea monitor for fatigue monitor for rash monitor liver function tests |
| gptkbp:formulation |
film-coated tablet
|
| gptkbp:has_ability |
300 mg
|
| https://www.w3.org/2000/01/rdf-schema#label |
Piqray
|
| gptkbp:indication |
gptkb:HR-positive_breast_cancer
|
| gptkbp:ingredients |
gptkb:alpelisib
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:is_used_for |
treatment of breast cancer
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States |
| gptkbp:pharmacokinetics |
oral bioavailability
half-life of 5 to 7 hours inhibits P I3 K alpha |
| gptkbp:population |
postmenopausal women
|
| gptkbp:requires |
available online
|
| gptkbp:research_focus |
quality of life assessments
combination therapies long-term outcomes resistance mechanisms biomarkers for response |
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea vomiting decreased appetite diarrhea rash hyperglycemia elevated liver enzymes stomatitis |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
P I3 K pathway
|
| gptkbp:type_of_care |
important for efficacy
|